Lupin is currently trading at Rs. 1901.10, up by 1.40 points or 0.07% from its previous closing of Rs. 1899.70 on the BSE.
The scrip opened at Rs. 1900.70 and has touched a high and low of Rs. 1910.00 and Rs. 1865.75 respectively. So far 51,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1343.00 on 17-Dec-2014.\
Last one week high and low of the scrip stood at Rs. 1947.40 and Rs. 1865.75 respectively. The current market cap of the company is Rs. 85,508.00 crore.
The promoters holding in the company stood at 46.56 % while Institutions and Non-Institutions held 43.45 % and 9.99 % respectively.
Pharma Major Lupin has received final approval for its Donepezil Hydrochloride Tablets, 23 mg from the United States Food and Drug Administration (US FDA) to market a generic version of Eisai Inc.’s Aricept Tablets, 23mg. Lupin’s US subsidiary, Lupin Pharmaceuticals Inc. would commence promoting the product shortly in the US.
Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc.'s Aricept Tablets, 23mg and is indicated for the treatment of dementia of the Alzheimer's type. Aricept had US sales of $52.3 million (IMS MAT June 2015).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |